↓ Skip to main content

Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody

Overview of attention for article published in Alzheimer's Research & Therapy, April 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)

Mentioned by

news
7 news outlets
blogs
2 blogs
twitter
2 tweeters
patent
3 patents
wikipedia
1 Wikipedia page
video
1 video uploader

Citations

dimensions_citation
138 Dimensions

Readers on

mendeley
181 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Safety and tolerability of BAN2401 - a clinical study in Alzheimer’s disease with a protofibril selective Aβ antibody
Published in
Alzheimer's Research & Therapy, April 2016
DOI 10.1186/s13195-016-0181-2
Pubmed ID
Authors

Veronika Logovinsky, Andrew Satlin, Robert Lai, Chad Swanson, June Kaplow, Gunilla Osswald, Hans Basun, Lars Lannfelt

Abstract

Several monoclonal antibodies for the treatment of Alzheimer's disease (AD) have been in development over the last decade. BAN2401 is a monoclonal antibody that selectively binds soluble amyloid β (Aβ) protofibrils. Here we describe the first clinical study with BAN2401. Safety and tolerability were investigated in mild to moderate AD. A study design was used with staggered parallel single and multiple ascending doses, from 0.1 mg/kg as a single dose to 10 mg/kg biweekly for four months. The presence of amyloid related imaging abnormalities (ARIA, E for edema, H for hemorrhage) was assessed with magnetic resonance imaging (MRI). Cerebrospinal fluid (CSF) and plasma samples were analyzed to investigate pharmacokinetics (PK) and effects on biomarkers. The incidence of ARIA-E/H on MRI was comparable to that of placebo. BAN2401 exposure was approximately dose proportional, with a serum terminal elimination half-life of ~7 days. Only a slight increase of plasma Aβ(1-40) was observed but there were no measurable effects of BAN2401 on CSF biomarkers. On the basis of these findings Phase 2b efficacy study has been initiated in early AD. BAN2401 was well-tolerated across all doses. The PK profile has guided us for selecting dose and dose regimens in the ongoing phase 2b study. There was no clear guidance for an effective dose based on biomarkers. NCT01230853 ClinicalTrials.gov Registered October 27, 2010.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 181 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Egypt 2 1%
United States 1 <1%
Greece 1 <1%
India 1 <1%
Unknown 176 97%

Demographic breakdown

Readers by professional status Count As %
Student > Bachelor 29 16%
Student > Master 23 13%
Researcher 21 12%
Student > Ph. D. Student 19 10%
Other 17 9%
Other 29 16%
Unknown 43 24%
Readers by discipline Count As %
Biochemistry, Genetics and Molecular Biology 29 16%
Medicine and Dentistry 29 16%
Neuroscience 18 10%
Pharmacology, Toxicology and Pharmaceutical Science 16 9%
Agricultural and Biological Sciences 12 7%
Other 27 15%
Unknown 50 28%

Attention Score in Context

This research output has an Altmetric Attention Score of 72. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 September 2022.
All research outputs
#489,301
of 22,359,063 outputs
Outputs from Alzheimer's Research & Therapy
#57
of 1,177 outputs
Outputs of similar age
#9,809
of 281,616 outputs
Outputs of similar age from Alzheimer's Research & Therapy
#1
of 1 outputs
Altmetric has tracked 22,359,063 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 97th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,177 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 23.7. This one has done particularly well, scoring higher than 95% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 281,616 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 1 others from the same source and published within six weeks on either side of this one. This one has scored higher than all of them